Clinical Trial Update: Prevention of Bone Loss After Acute SCI by Zoledronic Acid [Phase 2]

View source ↗

Summary

A Phase 2 trial testing zoledronic acid to prevent bone loss after acute spinal cord injury has completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Spinal Cord Injury

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Northwestern University | Conditions: Spinal Cord Injury, Acute Spinal Cord Injury | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02